Comparative Effectiveness of COVID-19 Vaccines in Preventing Infections and Disease Progression from SARS-CoV-2 Omicron BA.5 and BA.2, Portugal
Open accessAbstract
We estimated comparative primary and booster vaccine effectiveness (VE) of SARS-CoV-2 Omicron BA.5 and BA.2 lineages against infection and disease progression. During April-June 2022, we implemented a case-case and cohort study and classified lineages using whole-genome sequencing or spike gene target failure. For the case-case study, we estimated the adjusted odds ratios (aORs) of vaccination using a logistic regression. For the cohort study, we estimated VE against disease progression using a penalized logistic regression. We observed no reduced VE for primary (aOR 1.07 [95% CI 0.93-1.23]) or booster (aOR 0.96 [95% CI 0.84-1.09]) vaccination against BA.5 infection. Among BA.5 case-patients, booster VE against progression to hospitalization was lower than that among BA.2 case-patients (VE 77% [95% CI 49%-90%] vs. VE 93% [95% CI 86%-97%]). Although booster vaccination is less effective against BA.5 than against BA.2, it offers substantial protection against progression from BA.5 infection to severe disease.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Some studies classified people with missing vaccination information as unvaccinated.
“For example, some studies classified people with missing vaccination information as unvaccinated [30, 31].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
The citation lists haven’t been fetched yet
References 18 · Cited by 13
- Authors
- Kislaya, I., Casaca, P., Borges, V., Sousa, C., Ferreira, B. I., Fonte, A., Fernandes, E., Dias, C. M., Duarte, S., Almeida, J. P., Grenho, I., Coelho, L., Ferreira, R., Ferreira, P. P., Borges, C. M., Isidro, J., Pinto, M., Menezes, L., Sobral, D., Nunes, A., Santos, D., Gonçalves, A. M., Vieira, L., Gomes, J. P., Leite, P. P., Nunes, B., Machado, A., & Peralta-Santos, A.
- Affiliations
- Algarve Biomedical Center (PT)
- Corresponding author
- Kislaya, Irina
- ORCID
- Kislaya, Irina
- Casaca, Pedro
- Borges, Vítor
- Sousa, Carlos
- Ferreira, Bibiana I.
- Fernandes, Eugénia
- Dias, Carlos Matias
- Duarte, Sílvia
- Grenho, Inês
- Coelho, Luís
- Ferreira, Rita
- Ferreira, Patrícia Pita
- Isidro, Joana
- Pinto, Miguel
- Sobral, Daniel
- Nunes, Alexandra
- Santos, Daniela
- Gomes, João Paulo
- Leite, Pedro Pinto
- Nunes, Baltazar
- Machado, Ausenda
- Venue
- Emerging Infectious Diseases
- Published
- 2023-03
- Volume
- 29
- Issue
- 3
- Pages
- 569-575
- ISSN
- 1080-6040 (ISSN-L)
- 1080-6059
- PMC
- PMC9973705
- OpenAlex
- W4319215925
- Cited by
- 13
- References
- 18
- Citations by year
- 2025: 3 · 2024: 6 · 2023: 4
- FWCI
- 2.69
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by
- Locations
- Emerging infectious diseases (publishedVersion, cc-by)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- COVID-19 vaccines, SARS-CoV-2 Omicron BA.2, vaccine effectiveness, booster vaccination, disease progression, hospitalization, infection control, whole genome sequencing, Portugal
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, Humans, Portugal, Cohort Studies, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
